CLNN - InvestorNewsBreaks - Clene Inc. (NASDAQ: CLNN) Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational first-in-class therapy designed to improve central nervous system cells’ survival and function. Clene, which is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), presented the results at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in Florida. The results were gathered from the VISIONARY-MS trial long-term open label extension (“LTE”) in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow-up. According to the announcement, data gathered from the clinical trial indicate that long-term CNM-Au8 treatment results in “significant and clinically meaningful” improvement of vision and improvement of cognition. In addition, the company noted that treatment was well-tolerated, with no serious adverse events attributed to CNM-Au8 and no significant safety findings reported. The report noted that after completion of the double-blind period, 55 of 69 LTE-eligible study participants continued on CNM-Au8 30mg for up to an additional 96 weeks.
To view the full press release, visit https://ibn.fm/oVLIB
About Clene Inc.
Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN